Printer Friendly

DRUGS TARGETED TO CANCER TUMORS BY HYAL'S DRUG DELIVERY TECHNOLOGY

 MISSISSAUGA, Ontario, July 12 /PRNewswire/ -- The enhanced delivery and targeting of drugs to cancer tumors was confirmed in studies using Hyal Pharmaceutical Corporation's (NASDAQ-NMS: HYALF) Hyaluronic Acid (HA) drug delivery system, in formulation with the anti-cancer drug 5-Fluorouracil (5-FU). These results were presented today at the VI International Conference on Regional Cancer Treatment being held in Weisbaden, Germany. Dr. E.S. Klein, deputy chief of Surgical Oncology at the Sheba Medical Centre in Israel, reported that in studies using animals with either mammary or bladder cancers, the uptake of 5FU into the cancer was significantly higher when formulated with HA than when 5FU was administered alone. Furthermore, the anti-cancer drug, when formulated with HA, was retained by the cancer for significantly longer periods of time than when given alone. The results in cancer tissue contrast to those in normal tissue (control), where HA did not enhance uptake or retention of 5FU, confirming the Company's claim that its technology targets sites of disease.
 By targeting the cancer tissue and not the normal tissue, Hyal's formulations enhance the uptake and retention of anti-cancer drugs into tumors, thus improving the drug's capacity to destroy the cancer and increasing the patient's tolerability to the drug.
 Hyal specializes in the development and worldwide commercialization of pharmaceutical formulations utilizing its proprietary Hyaluronic Acid based drug delivery technology. Hyal is currently conducting Phase III clinical trials at 14 independent centers in Canada, the U.S.A., Australia and a number of European countries for its three lead products: HYAL-CT1101 for the treatment of basal cell carcinoma, HYAL- AT2101 for the topical treatment of pain and HYAL-AV2201 for the intravenous treatment of moderate to severe pain.
 Hyal Pharmaceutical Corporation's shares are listed on the Toronto Stock Exchange under the trading symbol HPC and on NASDAQ National Market System under the trading symbol HYALF.
 -0- 7/12/93
 /CONTACT: Samuel S. Asculai, president and CEO, 416-366-4863, or David W. Harper, vice president-development, 416-366-4863, both of Hyal Pharmaceuticals Corporation; or Diane Perry, 212-661-8030, or Kathy Brunson, 312-266-7800, both of the Financial Relations Board for Hyal Pharmaceutical Corporation/
 (HYALF)


CO: Hyal Pharmaceutical Corporation ST: Ontario IN: MTC SU:

TS -- NY025 -- 0310 07/12/93 10:03 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 12, 1993
Words:366
Previous Article:CAREMARK TO MANAGE OKLAHOMA CITY CLINIC
Next Article:BOSTON CHICKEN COOKS UP GROWTH IN PITTSBURGH
Topics:


Related Articles
HYAL ANNOUNCES PATENT DEVELOPMENTS
HYAL PHARMACEUTICAL NASDAQ LISTING EFFECTIVE
HYAL PHARMACEUTICAL REPORTS HIGH EFFICACY LEVELS FROM FIRST PHASE III TRIAL
HYAL'S NEW AND UNEXPECTED MECHANISM FOR PAIN RELIEF
HYAL PHARMACEUTICAL PROVIDES DEVELOPMENT UPDATE AT SPROTT HEALTH CARE CONFERENCE
HYAL ANNOUNCES SECOND PHASE III CLINICAL TRIAL FOR TOPICAL PAIN PRODUCT
HYAL ANNOUNCES ITS FIRST PHASE III CLINICAL TRIAL FOR INJECTABLE, INTRAVENOUS PAIN PRODUCT ALL LEAD PRODUCTS NOW IN PHASE III
POTENTIAL FOR HYAL PRODUCTS IN HEART DISEASE: PREVENTION OF RESTENOSIS TARGETED BY HYAL'S DRUG DELIVERY TECHNOLOGY
Hyal Reports Phase III Results From Its Hyanalgese-D(TM) Clinical Trial
Hyal & Shire Announce Phase III Results of HyClinda(TM)

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters